Castle biosciences presents data demonstrating decisiondx-melanoma as significant, independent predictor of recurrence in stage i cutaneous melanoma population

Friendswood, texas--(business wire)---- $cstl #aadvmx2021--castle biosciences, inc. (nasdaq: cstl), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, will present data at the american academy of dermatology's virtual meeting experience, being held april 23 – 25, 2021. the company has two poster presentations highlighting its decisiondx®-melanoma and decisiondx®-scc genomic tests. data presentation information is as follows: decisiondx®-melanoma: the p
CSTL Ratings Summary
CSTL Quant Ranking